摘要
动脉粥样硬化性疾病是心脑血管疾病的主要病因之一,动脉斑块的形成导致血管狭窄,循环系统血流障碍,从而导致组织缺氧而引发一系列心脑血管疾病,严重狭窄或斑块破裂形成血栓可导致循环血管闭塞,从而导致组织坏死,增加心脑血管疾病致死风险。目前动脉粥样硬化的治疗手段主要是针对循环中血脂水平的降低,他汀类药物仍然是一线降脂药物,尽管他汀类药物已经被证实具有良好的疗效和广泛适用性,但由于其剂量依赖性和副作用,相当一部分患者在血脂水平未达到指南推荐的标准时就不得不停用,因此,开发除他汀类药物之外能够降低血脂水平并具有良好疗效和耐受性的替代治疗药物具有重要意义。本篇文章主要综述目前针对动脉粥样硬化性心脑血管疾病的降脂新型药物的作用机制及临床研究进展,以期为动脉粥样硬化降脂治疗提供新的诊疗思路。
Atherosclerotic diseases are one of the main etiology of cardiovascular and cerebrovascular diseases.The formation of arterial patch leads to the narrowing of vessel and the blood flow disorder of circulation system,which leads to tissue hypoxia and leads to a series of cardiovascular and cerebrovascular diseases.Severe narrowing or patch rupture to form thrombus can lead to occlusion of circulating vessel,resulting in tissue necrosis,which increases the risk of death from cardiovascular and cerebrovascular diseases.At present,the treatment of atherosclerosis is mainly aimed at the reduction of blood lipid level in circulation,and statins are still the first-line hypolipidemic.Although statins have been proven to have good efficacy and wide applicability,due to their dose-dependence and side effects,a considerable number of patients have to stop using them when their blood lipid levels do not meet the standards recommended by the guidelines.Therefore,it is of great significance to develop replacement treatment drugs in addition to statins that can reduce blood lipid levels and have good efficacy and tolerance.This article mainly reviews the mechanism of action and clinical research progress of new hypolipidemic for atherosclerotic cardiovascular and cerebrovascular diseases,in order to provide a new diagnosis and treatment idea for atherosclerotic lipid-lowering therapy.
作者
刘惠
蒋萌
束宁德
刘庆新
LIU Hui;JIANG Meng;SHU Ningde;LIU Qingxin(Department of Neurology,Binzhou Medical University Hospital,Binzhou 256603,China;不详)
出处
《中国医学创新》
CAS
2024年第5期157-164,共8页
Medical Innovation of China
基金
山东省医药卫生科技发展计划项目(2017WS157)
滨州医学院科研计划与科研启动基金项目(BY2019KJ07)。
关键词
心脑血管疾病
动脉粥样硬化
降脂治疗
降脂药物
Cardiovascular and cerebrovascular diseases
Atherosclerosis
Lipid-lowering therapy
Hypolipidemic
